Martinez Bueno A, Molina MA, Fielding A, et al. Disruptive mutations in TP53 associate with survival benefit in a PARPi trial in ovarian cancer. ESMO 2017, abstract LBA42.
OLVG start met immunotherapie voor long- en niercelkanker
jul 2017 | Longoncologie, Uro-oncologie